ArticleThe Lancet regional health. Southeast Asia2026
Healthcare utilisation, expenditure, and admission-based mortality associated with paediatric hepatobiliary diseases in Thailand: a national database analysis (2015-2023).
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Population-level epidemiological data on paediatric hepatobiliary diseases (HBD) are limited in Southeast Asia. We aimed to quantify national trends in healthcare utilisation, expenditure, and admission-based mortality associated with paediatric HBD in Thailand. Methods: We conducted a retrospective cohort study of hospital admissions among individuals younger than 18 years of age using Thailand's National Health Security Office (NHSO) database from 2015 to 2023. HBD were identified using ICD-10-TM codes. To demonstrate the burden of HBD, we analysed admission rates (AR), length of stay (LOS), NHSO payments, and inpatient mortality rate (IMR). Sensitivity analyses excluding the COVID-19 pandemic years were performed. Findings: Among 60,916 admissions, 31,158 (51·1%) were male, and the median (IQR) age was 10 (3-14) years. The median (IQR) admission rate (AR) was 59·0 (56·1-65·9) per 100,000 population, with an AAPC of -0·61 (95% CI -2·90 to 1·68). Declining trends in AR were observed for several conditions, including acute hepatitis A, acute hepatitis B, hepatic failure, and cirrhosis. Infants had longer LOS, higher healthcare payments, and higher annual mortality (AM) rate than older children (all Interpretation: Paediatric HBD continue to impose a substantial burden on Thailand's healthcare system. Although overall inpatient mortality declined significantly over time, persistently high mortality in hepatic failure highlights ongoing gaps in specialised care. Strengthening referral pathways, critical care capacity, and access to liver care services may further improve outcomes for affected children. Funding: No funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.